brezosiran Updated Oct 29
The next catalyst for brezosiran is the planned initiation of a placebo-controlled pivotal study in 2027, pending regulatory alignment. Positive Phase 1b data (60-64% mean mHTT reduction) supports advancement, but the drug is still early-stage and represents a small part of Alnylam's diversified, approved-product portfolio. Watch for regulatory feedback and trial design details in 2027.
- Phase 1b data showed best-in-class huntingtin knockdown: mean 60-64% reduction of CSF mutant huntingtin at month 3 in the highest dose group, with individual reductions up to 83%, surpassing competitors like WVE-003 (46%).
- Encouraging safety and tolerability profile with potential for convenient twice-yearly dosing via intrathecal administration, which could enhance patient adherence.
- Alnylam plans a placebo-controlled pivotal study in 2027, which would be the first placebo-controlled test of the huntingtin 1a-lowering hypothesis, a potentially landmark trial.
- Phase 1b data do not establish clinical efficacy; the drug has not yet shown it can slow Huntington's disease progression, only that it lowers a biomarker (mHTT protein).
- Brezosiran is non-selective, lowering both normal and mutant huntingtin protein, which carries theoretical safety risk since normal huntingtin has important biological functions.
- The competitive landscape includes Wave Life Sciences' WVE-003 (allele-selective ASO with 46% mHTT reduction and FDA alignment for accelerated approval), and Roche's tominersen failure highlights how difficult it is to translate biomarker knockdown into clinical benefit in Huntington's.